The Competition Commission of Pakistan (CCP) on Friday approved the acquisition of trademarks for the pharmaceutical product ...

French private equity firm PAI Partners has submitted a new, higher offer for Sanofi's consumer health business Opella, the Le Monde newspaper said on Thursday, as PAI seeks to outbid U.S. rival ...

France’s Economy Minister has warned that the government could block the sale of a subsidiary of the French pharmaceutical ...

Clayton Dubilier & Rice is working on a package of commitments amid political concerns that its purchase of a controlling ...

The planned sale of France's best-selling medical drug to US investors has caused the government a splitting headache after ...

The French government is looking at options including taking a public stake in the consumer health business that Sanofi is in ...

Denali Therapeutics and Sanofi have decided to discontinue a drug trial aimed at treating multiple sclerosis. The experimental drug failed to achieve the necessary study goals, marking a setback in ...

Sanofi SA is in talks to sell a 50% controlling stake in its consumer health business to Clayton Dubilier & Rice, as the ...

PARIS, Oct 11 (Reuters) - Sanofi (SASY.PA), opens new tab has entered into talks to sell a controlling 50% stake in its consumer health business Opella to U.S. private equity firm Clayton Dubilier ...

With reports swirling about potential interest in Sanofi’s consumer health business, the French pharma has confirmed that a deal is indeed brewing. Sanofi has entered negotiations with private ...

Sanofi in talks to sell 50% stake in Opella for €15 billion ($16.4 billion). Goldman Sachs and Morgan Stanley arrange €6 billion in debt financing for buyers. According to the Bloomberg report ...

Sanofi has stopped a phase 2 trial of Denali Therapeutics-partnered oditrasertib in multiple sclerosis. The French drugmaker tore the RIPK1 inhibitor trial from its list of active studies after it ...